JP2024540196A5 - - Google Patents
Info
- Publication number
- JP2024540196A5 JP2024540196A5 JP2024525765A JP2024525765A JP2024540196A5 JP 2024540196 A5 JP2024540196 A5 JP 2024540196A5 JP 2024525765 A JP2024525765 A JP 2024525765A JP 2024525765 A JP2024525765 A JP 2024525765A JP 2024540196 A5 JP2024540196 A5 JP 2024540196A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21204904 | 2021-10-27 | ||
| EP21204904.3 | 2021-10-27 | ||
| PCT/EP2022/079744 WO2023072916A1 (en) | 2021-10-27 | 2022-10-25 | Antibodies targeting ccr2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540196A JP2024540196A (ja) | 2024-10-31 |
| JP2024540196A5 true JP2024540196A5 (https=) | 2025-11-05 |
| JPWO2023072916A5 JPWO2023072916A5 (https=) | 2025-11-05 |
Family
ID=78413745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525765A Pending JP2024540196A (ja) | 2021-10-27 | 2022-10-25 | Ｃｃｒ２を標的とする抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12168692B1 (https=) |
| EP (1) | EP4423131A1 (https=) |
| JP (1) | JP2024540196A (https=) |
| KR (1) | KR20240099211A9 (https=) |
| CN (1) | CN118159562A (https=) |
| AU (1) | AU2022378899A1 (https=) |
| CA (1) | CA3231124A1 (https=) |
| IL (1) | IL311476A (https=) |
| MX (1) | MX2024004447A (https=) |
| WO (1) | WO2023072916A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024245988A1 (en) * | 2023-05-29 | 2024-12-05 | Granite Bio Ag | Antibodies targeting ccr2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE102006015341A1 (de) | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Behandlung von multipler Sklerose und/oder rheumatoider Arthritis |
| JP5685535B2 (ja) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Ｃｃｒ２に対する抗体 |
| HK1208236A1 (en) | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| EP2727944A1 (en) * | 2012-10-30 | 2014-05-07 | Universitätsklinikum Regensburg | Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system |
| WO2016079276A1 (en) | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
-
2022
- 2022-10-25 JP JP2024525765A patent/JP2024540196A/ja active Pending
- 2022-10-25 AU AU2022378899A patent/AU2022378899A1/en active Pending
- 2022-10-25 CN CN202280072046.7A patent/CN118159562A/zh active Pending
- 2022-10-25 KR KR1020247013799A patent/KR20240099211A9/ko active Pending
- 2022-10-25 CA CA3231124A patent/CA3231124A1/en active Pending
- 2022-10-25 EP EP22812470.7A patent/EP4423131A1/en active Pending
- 2022-10-25 MX MX2024004447A patent/MX2024004447A/es unknown
- 2022-10-25 WO PCT/EP2022/079744 patent/WO2023072916A1/en not_active Ceased
- 2022-10-25 IL IL311476A patent/IL311476A/en unknown
-
2024
- 2024-08-02 US US18/793,279 patent/US12168692B1/en active Active
- 2024-11-06 US US18/938,749 patent/US20250059288A1/en active Pending